| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
|
Cavo, Michele
|
|
|
7 |
6 |
p. e456-e468
|
artikel
|
| 2 |
Coagulation abnormalities and thrombosis in patients with COVID-19
|
Levi, Marcel
|
|
|
7 |
6 |
p. e438-e440
|
artikel
|
| 3 |
Correction to Lancet Haematol 2020; 7: e456–68
|
|
|
|
7 |
6 |
p. e443
|
artikel
|
| 4 |
COVID-19 coagulopathy: an evolving story
|
The Lancet Haematology,
|
|
|
7 |
6 |
p. e425
|
artikel
|
| 5 |
Daratumumab: a game changer in myeloma therapy
|
Ludwig, Heinz
|
|
|
7 |
6 |
p. e426-e427
|
artikel
|
| 6 |
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
|
Usmani, Saad Z
|
|
|
7 |
6 |
p. e447-e455
|
artikel
|
| 7 |
Effect of the COVID-19 pandemic on cancer treatment and research
|
Saini, Kamal S
|
|
|
7 |
6 |
p. e432-e435
|
artikel
|
| 8 |
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial
|
Maggio, Aurelio
|
|
|
7 |
6 |
p. e469-e478
|
artikel
|
| 9 |
Extranodal natural-killer T-cell lymphoma: experience from China
|
Wang, Liang
|
|
|
7 |
6 |
p. e441
|
artikel
|
| 10 |
Haemophagocytic lymphohistiocytosis in pregnancy
|
Jawad, Sarah
|
|
|
7 |
6 |
p. e498
|
artikel
|
| 11 |
Intensification and consolidation therapy in multiple myeloma in the current era
|
Nadeem, Omar
|
|
|
7 |
6 |
p. e427-e429
|
artikel
|
| 12 |
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial
|
Thanarajasingam, Gita
|
|
|
7 |
6 |
p. e490-e497
|
artikel
|
| 13 |
Management of patients with multiple myeloma during the COVID-19 pandemic
|
Malard, Florent
|
|
|
7 |
6 |
p. e435-e437
|
artikel
|
| 14 |
Mitigating the effect of the COVID-19 pandemic on sickle cell disease services in African countries
|
Dexter, Daniel
|
|
|
7 |
6 |
p. e430-e432
|
artikel
|
| 15 |
Molecular imaging in lymphoma beyond 18F-FDG-PET: understanding the biology and its implications for diagnostics and therapy
|
Kahle, Xaver U
|
|
|
7 |
6 |
p. e479-e489
|
artikel
|
| 16 |
No child with a transfusion-dependent haemoglobinopathy left unchelated: are we there yet?
|
Bewersdorf, Jan Philipp
|
|
|
7 |
6 |
p. e429-e430
|
artikel
|
| 17 |
Richard Szydlo: making statistics in haematology count
|
Davies, Rachael
|
|
|
7 |
6 |
p. e444
|
artikel
|
| 18 |
Should the emphasis be on induction or consolidation therapy in transplant-eligible, newly diagnosed multiple myeloma?
|
Krishnan, Amrita
|
|
|
7 |
6 |
p. e445-e446
|
artikel
|
| 19 |
Survival outcomes for extranodal natural-killer T-cell lymphoma
|
Shibusawa, Motoharu
|
|
|
7 |
6 |
p. e442
|
artikel
|
| 20 |
Survival outcomes for extranodal natural-killer T-cell lymphoma – Authors' reply
|
Fox, Christopher P
|
|
|
7 |
6 |
p. e442
|
artikel
|
Tijdschrift beschrijving